United States · Series B startup

Who invested in Evozyne

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

AI

Funding summaryUpdated 26 Oct 2026

$81Mraised across 1 round since 2023, from 1 source

Latest round
Series B, $81MSept 2023
Investors
4
See who backed them

The rounds

  1. Sept 2023
    Series B$81M

    Source recordedSEC filing: $81M sold, first sale Sept 2023

Founders and team

From the SEC filings it signed: 9 on the team.

  • Mike S. GamsonPresident, Chief Executive Officer, and Directori
  • Patrick J. MorrisExecutive Vice President, Legal Affairs, Assistant Secretary, and Directori
  • Aris J. TheologisChief Business Officeri
  • Arjun S. RallapalliChief Operating Officeri
  • Darien S. ParhadChief Financial Officer and Treasureri
  • Rama J. RanganathanChief Scientific Officer and Directori
  • Aleina M. LeeCorporate Controlleri
  • Jeffrey S. AroninChairman and Directori
  • Jude M. SullivanGeneral Counsel and Secretaryi

On the board, as filediAntonio S. GraciasMatthew M. Rizzo

Everyone who backed them

OrbiMedPrivate equity1round
FidelityVC firm1round
nVenturesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists Evozyne as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Paragon BiosciencesAcceleratorPer its own site

Quick answers about Evozyne

Who invested in Evozyne?

Evozyne's investors include OrbiMed, Fidelity, Valor Equity Partners and nVentures.

How much has Evozyne raised?

Evozyne has raised $81M across 1 round since 2023.

When did Evozyne last raise?

Evozyne's most recent round was a Series B of $81M in Sept 2023.

What was Evozyne's biggest round?

Its most recent round, $81M in Sept 2023, is also its largest on record.

Who backed Evozyne first?

Evozyne's first round on record, in Sept 2023, was backed by OrbiMed, Fidelity and Valor Equity Partners and 1 others.

What stage is Evozyne at?

Evozyne's latest named round is a Series B, in Sept 2023.

Where is Evozyne based?

Evozyne is based in the United States.

Companies like Evozyne

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.